Biochemical failure as a determinant of distant metastasis and death in prostate cancer treated with radiotherapy

International Journal of Radiation Oncology Biology Physics

Volumn 57, Issue 1, 2003, Pages 19-23

  Pollack, Alan ^a   Hanlon, Alexandra L ^a   Movsas, Benjamin ^a   Hanks, Gerald E ^a   Uzzo, Robert ^a   Horwitz, Eric M ^a  

^a FOX CHASE CANCER CENTER   (United States)

Author keywords

Cause specific death; Prostate specific antigen; Radiotherapy

Indexed keywords

ANTIGENS; BIOCHEMISTRY; DISEASES; PATIENT TREATMENT; RADIOTHERAPY; TUMORS;

PROSTATE CANCERS;

ONCOLOGY;

PROSTATE SPECIFIC ANTIGEN;

ARTICLE; BEAM THERAPY; CANCER RADIOTHERAPY; CAUSE OF DEATH; CHEMICAL ANALYSIS; CONTROLLED STUDY; FOLLOW UP; HUMAN; KAPLAN MEIER METHOD; MAJOR CLINICAL STUDY; MALE; METASTASIS; MULTIVARIATE LOGISTIC REGRESSION ANALYSIS; PRIORITY JOURNAL; PROSTATE CANCER; RADIATION DOSE; TREATMENT FAILURE;

EID: 0041564148     PISSN: 03603016     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0360-3016(03)00538-8     Document Type: Article

References (29)

1. Cox J., Grignon D., Kaplan R., et al. Consensus statement Guidelines for PSA following radiation therapy . Int J Radiat Oncol Biol Phys. 37:1997;1035-1041.
2. Zagars G.K., Pollack A. The fall and rise of prostate-specific antigen Kinetics of serum prostate-specific antigen levels after radiation therapy for prostate cancer . Cancer. 72:1993;832-842.
3. Pollack A., Zagars G.K., Kavadi V.S. Prostate specific antigen doubling time and disease relapse after radiotherapy for prostate cancer. Cancer. 74:1994;670-678.
4. Zagars G.K., Pollack A. Kinetics of serum prostate-specific antigen after external beam radiation for clinically localized prostate cancer. Radiother Oncol. 44:1997;213-221.
5. Pound C., Partin A., Eisenberger M., et al. Natural history of progression after PSA elevation following radical prostatectomy. JAMA. 281:1999;1591-1597.
6. Horwitz E., Vicini F., Ziaja E., et al. The correlation between the ASTRO Consensus Panel definition of biochemical failure and clinical outcome for patients with prostate cancer treated with external beam irradiation. Int J Radiat Oncol Biol Phys. 41:1998;267-272.
7. Sandler H.M., Dunn R.L., McLaughlin P.W., et al. Overall survival after prostate-specific-antigen-detected recurrence following conformal radiation therapy. Int J Radiat Oncol Biol Phys. 48:2000;629-633.
8. Kupelian P.A., Buchsbaum J.C., Patel C., et al. Impact of biochemical failure on overall survival after radiation therapy for localized prostate cancer in the PSA era. Int J Radiat Oncol Biol Phys. 52:2002;704-711.
9. Kwan W, Pickles T. In regard to Kupelian, et al.: Impact of biochemical failure on overall survival after radiation therapy for localized prostate cancer in the PSA era. Int J Radiat Oncol Biol Phys 2002;52:704-711. Int J Radiat Oncol Biol Phys 2002;54:1577-1579.
10. Amling C.L., Blute M.L., Lerner S.E., et al. Influence of prostate-specific antigen testing on the spectrum of patients with prostate cancer undergoing radical prostatectomy at a large referral practice. Mayo Clin Proc. 73:1998;401-406.
11. Hankey B.F., Feuer E.J., Clegg L.X., et al. Cancer surveillance series Interpreting trends in prostate cancer - Part I: Evidence of the effects of screening in recent prostate cancer incidence, mortality, and survival rates . J Natl Cancer Inst. 91:1999;1017-1024.
12. Jhaveri F.M., Klein E.A., Kupelian P.A., et al. Declining rates of extracapsular extension after radical prostatectomy Evidence for continued stage migration . J Clin Oncol. 17:1999;3167-3172.
13. Ung J.O., Richie J.P., Chen M.H., et al. Evolution of the presentation and pathologic and biochemical outcomes after radical prostatectomy for patients with clinically localized prostate cancer diagnosed during the PSA era. Urology. 60:2002;458-463.
14. Schellhammer P.F., Moriarty R., Bostwick D., et al. Fifteen-year minimum follow-up of a prostate brachytherapy series Comparing the past with the present . Urology. 56:2000;436-439.
15. Chism D.B., Hanlon A.L., Troncoso P., et al. Impact on outcome of the Gleason score shift. Int J Radiat Oncol Biol Phys. 54:2002;265-266.
16. Smith E.B., Frierson H.F. Jr, Mills S.E., et al. Gleason scores of prostate biopsy and radical prostatectomy specimens over the past 10 years Is there evidence for systematic upgrading? Cancer. 94:2002;2282-2287.
17. Corn B.W., Hanks G.E., Schultheiss T.E., et al. Conformal treatment of prostate cancer with improved targeting Superior prostate-specific antigen response compared to standard treatment . Int J Radiat Oncol Biol Phys. 32:1995;325-330.
18. Horwitz E.M., Hanlon A.L., Pinover W.H., et al. Defining the optimal radiation dose with three-dimensional conformal radiation therapy for patients with nonmetastatic prostate carcinoma by using recursive partitioning techniques. Cancer. 92:2001;1281-1287.
19. Monti A.F., Ostinelli A., Frigerio M., et al. An ICRU 50 radiotherapy treatment chart. Radiother Oncol. 35:1995;145-150.
20. Kaplan E.L., Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc. 53:1958;447-457.
21. Cox D.R. Regression models and life tables. J Roy Stat Soc. 34:1972;187-220.
22. Vicini F., Kestin L., Martinez A. The importance of adequate follow-up in defining treatment success after external beam irradiation for prostate cancer. Int J Radiat Oncol Biol Phys. 45:1999;553-561.
23. Trapasso J.G., deKernion J.B., Smith R.B., et al. The incidence and significance of detectable levels of serum prostate specific antigen after radical prostatectomy. J Urol. 152:1994;1821-1825.
24. Fowler J.E. Jr, Pandey P., Seaver L.E., et al. Prostate specific antigen regression and progression after androgen deprivation for localized and metastatic prostate cancer. J Urol. 153:1995;1860-1865.
25. Hancock S.L., Cox R.S., Bagshaw M.A. Prostate specific antigen after radiotherapy for prostate cancer A reevaluation of long-term biochemical control and the kinetics of recurrence in patients treated at Stanford University . J Urol. 154:1995;1412-1417.
26. Jhaveri F.M., Klein E.A. How to explore the patient with a rising PSA after radical prostatectomy Defining local versus systemic failure . Semin Urol Oncol. 17:1999;130-134.
27. Hanlon A.L., Diratzouian H., Hanks G.E. Posttreatment prostate-specific antigen nadir highly predictive of distant failure and death from prostate cancer. Int J Radiat Oncol Biol Phys. 53:2002;297-303.
28. Vicini F.A., Kestin L.L., Martinez A.A. The correlation of serial prostate specific antigen measurements with clinical outcome after external beam radiation therapy of patients for prostate carcinoma. Cancer. 88:2000;2305-2318.
29. Kestin L.L., Vicini F.A., Martinez A.A. Practical application of biochemical failure definitions What to do and when to do it . Int J Radiat Oncol Biol Phys. 53:2002;304-315.